Published October 10, 2023
Cellevate raises 39 million SEK in Seed Financing to accelerate their global commercial launch
LUND, Sweden – Cellevate, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announced today the successful closure of its recent investment round, securing a total of 39 million SEK. The round was led by Industrifonden, in syndication with the European Innovation Council Fund (EIC Fund) and…
Published October 10, 2023
Cellevate tar in 39 miljoner kronor i såddfinansiering för att accelerera global kommersiell lansering
LUND, Sverige – Cellevate, ett innovativt bioteknikföretag som utvecklar nästa generations cellodlingssystem som är utformat för att revolutionera dagens bioproduktion, meddelade idag att företaget framgångsrikt har avslutat sin senaste investeringsrunda och därmed säkrat totalt 39 miljoner kronor. Rundan leddes av Industrifonden, i samarbete med European Innovation Council Fund (EIC Fund) och Onsight Ventures. Cellevates egenutvecklade…
Published October 9, 2023
Cellevate to present at LSX Nordics Congress in Copenhagen on October 11, 2023
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announced that Laura Chirica, CEO, will present at the LSX Nordics Congress in Copenhagen, Denmark. Event details – Cellevate presentation:Day: Wednesday, October 11, 2023Time: Presentation at 11:30 am (CET) For more information, please…
Published July 6, 2023
Cellevate participates at GLIA 2023 in Berlin, July 8-11 to promote Cellevat3d™ NanoMatrice™ – a neuro-scaffold designed for research of the central nervous system
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems, will be participating at the 16th European Meeting on Glial Cells in Health and Disease in Berlin, Germany, on July 8-11, 2023, focused on enhancing public awareness for the glial cells in the central nervous system, and for…
Published June 20, 2023
Cellevate and Max Planck Society enters into collaboration for research in viral vaccine production
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that the company has entered into collaboration with the Max Planck Society, represented by the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg, Germany. The Max Planck Society…
Published May 29, 2023
Cellevate strengthens its Scientific Advisory Board with appointment of Dr. Yvonne Genzel, a leading expert in vaccine production using cell culture-based virus processes
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that PD Dr. Yvonne Genzel, has been appointed to the company’s Scientific Advisory Board. Dr. Genzel is since 2001 member of the Bioprocess Engineering group at the Max-Planck-Institute for Dynamics of…
Published May 4, 2023
Cellevate appoints Dr. Thierry Ziegler, a leading expert in biopharmaceutical development, to the Scientific Advisory Board
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that Dr. Thierry Ziegler, has been appointed to the company’s Scientific Advisory Board. Dr. Ziegler has more than 25 years of experience and expertise in biopharmaceutical development and production with the…
Published May 3, 2023
AdBIOPRO, Competence Centre for Advanced BioProduction secures 112 mkr funding
LUND, Sweden – As Cellevate published in the news on March 27, 2023, the company is one of the technology providers in the AdBIOPRO consortium with supplying nanofiber-based technology for Upstream AAV (adeno-associated virus), lentivirus and cell therapy bioproduction. The AdBIOBRO consortium today released the news about securing 112 mkr funding, which will enable AdBIOPRO…
Published April 26, 2023
Positive feasibility results for AAV vector transfection and production using Cellevat3d™ microcarriers
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announces positive feasibility results in a collaborative study performed by RISE Research Institutes of Sweden. In this Vinnova-funded project, the results showed that Cellevat3d™ microcarriers are highly effective in promoting the growth of…
Published March 29, 2023
Cellevate expands the collaboration with the University of Dundee, UK, to optimize the use of the Cellevat3d™ microcarriers in AAV based production for cell and gene therapy
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, has expanded the collaboration with the University of Dundee in the UK to perform cell culture experiments as one of the partners engaged in the validation program of the Cellevat3d™ microcarriers in cell…
